

“Nov. 14, 2002 – Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of Cafergot with potent CYP A4 inhibitors., including protease inhibitors and macrolide antibiotics, the US. Food and Drug Administration reported. Cafergot is indicated for the treatment of migraine and vascular headache.

“CYP 3A4 inhibition elevates the serum levels of Cafergot (a combination of ergotamine Tartrate and caffeine), which increases the risk of vasospasm leading to cerebral ischemia and/or ischemia of the extremities. Because of increased risk of serious vasospastic adverse events, concomitant use of these medications is contraindicated.” Information from Medscape

For more information, see the following web site
www.medscape.com/viewarticle/444645?mpid=6249.